A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors. After a pre-randomisation period during which positron emission tomography computed tomography (PET/CT) and MRI will be conducted, patients will be randomized to receive either RO4607381 600mg po daily, or placebo po daily. PET/CT and MRI scans will be taken at intervals during the study. The anticipated time on study treatment is 2 years, and the target sample size is 100 individuals.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Dalcetrapib

Criteria

Inclusion Criteria:

• adult patients, 18-75 years of age;

• CHD, including patients with other CHD risk factors;

• treated appropriately for dyslipidemia;

• clinically stable.

Exclusion Criteria:

• previous exposure to any cholesteryl ester transfer protein (CETP) inhibitor or vaccine;

• recent (within 3 months) clinically significant coronary events, transient ischemic attacks or cerebrovascular accident;

• severe anemia;

• uncontrolled hypertension;

• poorly controlled diabetes.